Davis's Drug Guide
alemtuzumab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
**REMS Drug**
Pronunciation:
a-lem-too-zoo-mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Lemtrada
- MabCampath
Ther. Class.
anti-multiple sclerosis agents
Pharm. Class.
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Alemtuzumab." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. www.drugguide.com/ddo/view/Davis-Drug-Guide/51021/all/alemtuzumab.
Vallerand AHA, Sanoski CAC, Quiring CC. Alemtuzumab. Davis's Drug Guide. F.A. Davis Company; 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51021/all/alemtuzumab. Accessed December 10, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Alemtuzumab. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51021/all/alemtuzumab
Vallerand AHA, Sanoski CAC, Quiring CC. Alemtuzumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 December 10]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51021/all/alemtuzumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - alemtuzumab
ID - 51021
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51021/all/alemtuzumab
PB - F.A. Davis Company
ET - 18
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -